Ruxolitinib 1.5 %

Alternative Names: Opzelura

Ruxolitinib (Opzelura) is a topical JAK1/JAK2 inhibitor approved for mild to moderate eczema in patients 12 and older who haven’t responded well to other topical treatments. It works by blocking inflammatory pathways that cause itching, redness, and skin irritation. Unlike steroids, it’s safe to use on sensitive areas like the face and neck and offers fast itch relief, often within days.

Common side effects include mild burning or redness at the application site, and it should be used on limited areas due to potential systemic absorption. It’s a good non-steroidal option for patients needing targeted, fast-acting eczema treatment.

 

 

 

 

 

 

 

Treatment Type: Prescription Medication

Treatment Class: N/A

Treatment Modality: N/A

Ruxolitinib 1.5 %

Review Summary

4.0

1 Reviews

Preferred by 1 Reviewers

Based on the provided review, Ruxolitinib 1.5% cream appears to be an effective, non-steroidal treatment for eczema, offering rapid relief and being particularly useful for patients with sensitive areas or steroid intolerance. The review suggests it is a promising alternative to standard eczema therapies, with a positive rating of 4 out of 5.

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
3
1 = Very Expensive 5 = Very Affordable

3

Moderate Cost
Relief Speed
4
1 = No Relief 5 = Immediate Relief

4

Fast Relief
Side Effects
5
1 = Intolerable Effect 5 = No Effect

5

No Effect
Treatment Line
3
1 = Third-line or more 5 = First-line

3

Second Line

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

4.0

1 Reviews
5
0%
4
100%
3
0%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the provided review, Ruxolitinib 1.5% cream appears to be an effective, non-steroidal treatment for eczema, offering rapid relief and being particularly useful for patients with sensitive areas or steroid intolerance. The review suggests it is a promising alternative to standard eczema therapies, with a positive rating of 4 out of 5.

Reviews

Filter by reviewer type Pro

Select all Clear all

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
1 year ago
Ruxolitinib cream is a novel, non-steroidal, and highly targeted option for treating eczema, especially in patients with sensitive areas, steroid intolerance, or partial response to standard therapies. It offers rapid relief and is generally well tolerated when used as directed. However, judicious use is critical due to its potential for systemic effects if overused.
View Professional Disclosures

Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.

We use cookies to personalize our services and provide you with the best possible experience. By continuing to use this site, you agree to this cookie usage. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can learn more about cookies and how your data is processed in the Privacy Policy.

Strictly Necessary Only Accept All